Contract W911SR26FA005
Emergent Biodefense Operations Lansing Llc · Department Of Defense · January 8, 2026
Emergent Biodefense Operations Lansing Llc was awarded a federal contract by Department Of Defense (Department Of The Army) on January 8, 2026 for $7.18 million of work in medicinal and botanical manufacturing. Performance is in Lansing, MI. This is a task or delivery order issued under parent IDIQ W911SR24D0001. It uses firm fixed-price contract pricing. If all options are exercised, the contract could reach $66.88 million.
Contract details
- PIID
- W911SR26FA005
- Parent IDIQ
- W911SR24D0001
- Award type
- Delivery Order
- Pricing
- Firm Fixed Price
- Competition
- Not Available For Competition
- NAICS
- 325411 · Medicinal And Botanical Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Lansing, MI
- First action
- January 8, 2026
Description
FOR THE PROCUREMENT OF BIOTHRAX (ANTHRAX VACCINE ABSORBED (AVA))
Modification timeline
-
January 8, 2026Base award$7.18M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Amerisourcebergen Drug Corp | Department Of Defense | January 1, 2026 | $232 |
| Amerisourcebergen Drug Corp | Department Of Defense | January 1, 2026 | $13.1K |
| Amerisourcebergen Drug Corp | Department Of Defense | January 1, 2026 | $1.9K |
| Amerisourcebergen Drug Corp | Department Of Defense | January 1, 2026 | $220.9K |
| Amerisourcebergen Drug Corp | Department Of Defense | January 1, 2026 | $135 |
| Amerisourcebergen Drug Corp | Department Of Defense | January 1, 2026 | $39.8K |
Top contractors in NAICS 325411
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 372,977 | $24.02B |
| 2 | Amerisourcebergen Drug Corp | 1,414,856 | $18.32B |
| 3 | Glaxosmithkline, Llc | 44 | $5.42B |
| 4 | Merck Sharp & Dohme Llc | 3 | $1.50B |
| 5 | Novartis Vaccines And Diagnostics, Inc. | 132 | $1.07B |
| 6 | Sanofi Vaccines Us Inc. | 57 | $650.53M |
| 7 | Cardinal Health, Inc. | 42,916 | $603.29M |
| 8 | Dms Pharmaceutical Group Inc | 113,930 | $547.06M |
| 9 | Cardinal Health 100, Inc | 7,655 | $486.24M |
| 10 | Glaxosmithkline Holdings (Americas) Inc. | 72 | $280.01M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract W911SR26FA005?
Contract W911SR26FA005 is a federal contract awarded to Emergent Biodefense Operations Lansing Llc by Department Of Defense on January 8, 2026 for $7.18 million of work classified under MEDICINAL AND BOTANICAL MANUFACTURING. It has been modified 0 times since the base award.
Who won contract W911SR26FA005?
Emergent Biodefense Operations Lansing Llc won contract W911SR26FA005 from Department Of Defense.
How much is contract W911SR26FA005 worth?
Contract W911SR26FA005 has obligated $7.18 million to date, with a total potential value of $66.88 million if all options are exercised.